Comparison of the molecular coupling of the PLX4032 drug and the RNP CRISPR/CPF1 biopharmaceitical targeted to the metastatic melanoma type BRAF-V600E

Other

Abstract:

Palabras claves:

Autores:

Alvarado Y.J., Bastidas M., González-Paz L.A., Lossada C.A., Luis S. Moncayo, Parra M.M., Pérez A.E., Sierra C.

Fuentes:

scopus